Mifepristone versus placebo to treat uterine myoma: A double-blind, randomized clinical trial

International Journal of Women's Health

Volumn 5, Issue 1, 2013, Pages 361-369

  Esteve, Josep Lluis Carbonell ^a   Acosta, Rita ^b   Pérez, Yasmirian ^b   Rodriguez, Barbara ^b   Seigler, Isabel ^b   Sanchez, Carlos ^b   Tomasi, Giuseppe ^c  

^a Mediterranea Medica Clinic   (Spain)

^b Eusebio Hernandez Gynecology and Obstetrics Teaching Hospital   (Cuba)

^c UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

Author keywords

Antiprogestins; Fibroid; Leiomyoma; Mifepristone

Indexed keywords

ESTRADIOL; MIFEPRISTONE; PLACEBO;

ADULT; AGED; AMENORRHEA; ARTICLE; CONTROLLED STUDY; CUBA; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; ECHOGRAPHY; ENDOMETRIUM BIOPSY; ESTRADIOL BLOOD LEVEL; FATIGUE; FEMALE; HOT FLUSH; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MENORRHAGIA; METRORRHAGIA; NAUSEA; PELVIC PRESSURE; PELVIS PAIN SYNDROME; PELVIS RADIOGRAPHY; PREVALENCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RECTAL PAIN; SYMPTOM; TUMOR VOLUME; UTERUS MYOMA;

EID: 84879494971     PISSN: None     EISSN: 11791411     Source Type: Journal    
DOI: 10.2147/IJWH.S42770     Document Type: Article

References (19)

1. Eisinger SH, Meldrum S, Fiscella K, le Roux HD, Guzick DS. Low-dose mifepristone for uterine leiomyomata. Obstet Gynecol. 2003;101(2):243-250.
2. Eisinger SH, Bonfiglio T, Fiscella K, Meldrum S, Guzick DS. Twelve-month safety and efficacy of low-dose mifepristone for uterine myomas. J Min Invasiv Gynecol. 2005;12(3):227-233.
3. Eisinger SH, Fiscella J, Bonfiglio T, Meldrum S, Fiscella K. Open-label study of ultra low-dose mifepristone for the treatment of uterine leiomyomata. Eur J Obstet Gynecol. 2009;146(2):215-218.
4. Fiscella K, Eisinger SH, Meldrum S, Feng C, Fisher SG, Guzick DS. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size. A randomized controlled trial. Obstet Gynecol. 2006;108(6): 1381-1387.
5. Carbonell Esteve JL, Acosta R, Heredia B, Pérez Y, Castañeda MC, Hernández AV. Mifepristone for the treatment of uterine leiomyomas. Obstet Gynecol. 2008;112(5):1029-1036.
6. Carbonell JL, Quiróz Rámirez GM, Borge A, Castellón Zapata LE, Cuadra Aragón W, Giuseppe Tomasi G. [Mifepristone 5 mg versus 10 mg daily to treat leiomyoma]. Prog Obstet Ginecol. 2009;10:1-8. Spanish.
7. Carbonell JL, Acosta R, Pérez Y, Yero MC, Seigler I, Heredia B. [Evolution of uterine leiomyoma after treatment with mifepristone. Randomized clinical trial]. Prog Obstet Ginecol. 2010;53(6):231-236. Spanish.
8. Carbonell JL, Acosta R, Heredia B, et al. [Mifepristone to treat uterine fibroids]. Rev Cub Gynecol Salud Reprod. 2010;36(2). Spanish.
9. Esteve JL, Acosta R, Pérez Y, Campos R, Hernández AV, Texidó CS. Treatment of uterine myoma with 5 or 10 mg mifepristone daily during 6 months, post-treatment evolution over 12 months: double-blind randomised clinical trial. Eur J Obstet Gynecol Reprod Biol. 2012; 161(2):202-208.
10. Carbonell Esteve JL, Riverón AM, Cano M, et al. Mifepristone 2.5 mg versus 5 mg daily in the treatment of leiomyoma before surgery. Int J Womens Health. 2012;4:75-84.
11. Carbonell JL, Acosta R, Pérez Y, et al. Safety and effectiveness of different dosage of mifepristone for the treatment of uterine fibroids: a double-blind randomized clinical trial. Int J Womens Health. 2013;5: 115-124.
12. Engman M, Granberg S, Williams AR, Meng CX, Lalitkumar PG, Gemzell-Danielsson K. Mifepristone for treatment of uterine leiomyoma. A prospective randomized placebo controlled trial. Hum Reprod. 2009;24(8):1870-1879.
13. http://www.ema.europa.eu. EPAR summary for the public. Available from http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002041/WC500124089.pdf. Accessed April 3, 2013.
14. Fiscella F, Bonfiglio T, Winters P, Eisinger SH, Fiscella K. Distinguishing features of endometrial pathology after exposure to the progesterone receptor modulator mifepristone. Hum Pathol. 2011;42(7):947-953.
15. Bagaria M, Suneja A, Vaid NB, Guleria K, Mishra K. Low-dose mifepristone in treatment of uterine leiomyoma: a randomized double-blind placebo-controlled trial. Aust N Z J Obstet Gynaecol. 2009;49(1): 77-83.
16. Management of Uterine Fibroids. AHRQ Publication NO 01-E051. Evidence report/technology assessment: Number 34. Rockville, MD: Agency for Healthcare Research and Quality; 2001. Available from: http://archive.ahrq.gov/clinic/epcsums/utersumm.htm. Accessed May 11, 2012.
17. Horne FM, Blithe DL. Progesterone receptor modulators and the endometrium: changes and consequences. Hum Reprod Update. 2007; 13(6):567-580.
18. Mutter GL, Bergeron C, Deligdisch L, et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod Pathol. 2008;21(5):591-598.
19. Spies JB, Coyne K, Guaou Guaou N, Boyle D, Skyrnarz-Murphy K, Gonzalves SM. The UFS-QOL, a new disease-specific and health-related quality of life questionnaire for leiomyoma. Obstet Gynecol. 2002;99(2):290-300.